OncoMatch/Clinical Trials/NCT06609005
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
Is NCT06609005 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies INV-9956 for advanced metastatic castration resistant prostate cancer.
Treatment: INV-9956 — This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: taxane
Received at least one prior line of taxane-based chemotherapy
Must have received: hormonal AR targeted therapy (abiraterone, enzalutamide)
at least one line of hormonal AR targeted therapy (eg, abiraterone, enzalutamide)
Lab requirements
Blood counts
adequate marrow function
Kidney function
adequate kidney function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Honor Health · Scottsdale, Arizona
- Hoag Family Cancer Institute · Newport Beach, California
- UC Irvine Medical Center · Orange, California
- Next Oncology - Houston · Houston, Texas
- UT Health · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify